Scarica l'app Stockscreener
1.93
0.52%
-0.01
Dopo l'orario di chiusura:
1.91
-0.02
-1.04%
Precedente Chiudi:
$1.94
Aprire:
$1.93
Volume 24 ore:
55,713
Relative Volume:
0.49
Capitalizzazione di mercato:
$280.73M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-8.5892
EPS:
-0.2247
Flusso di cassa netto:
-
1 W Prestazione:
-3.98%
1M Prestazione:
-9.39%
6M Prestazione:
-3.50%
1 anno Prestazione:
-19.92%
Intervallo 1D:
$1.91
$1.95
Intervallo di 1 settimana:
$1.90
$2.05
Portata 52W:
$1.66
$3.335
Immutep Limited Adr Stock (IMMP) Company Profile
Nome
Immutep Limited Adr
Settore
Industria
Telefono
-
Indirizzo
-
Confronta IMMP con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IMMP
Immutep Limited Adr
|
1.93 | 280.73M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.00 | 108.68B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
681.58 | 74.90B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
640.52 | 38.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
246.27 | 31.76B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
111.93 | 26.83B | 3.30B | -501.07M | 1.03B | -2.1146 |
Immutep Limited Adr Stock (IMMP) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-05-17 | Iniziato | CapitalOne | Overweight |
| 2023-08-03 | Iniziato | Robert W. Baird | Outperform |
| 2021-08-03 | Iniziato | Ladenburg Thalmann | Buy |
| 2021-07-16 | Ripresa | Maxim Group | Buy |
| 2018-09-28 | Iniziato | B. Riley FBR | Buy |
| 2018-02-15 | Reiterato | Maxim Group | Buy |
Mostra tutto
Immutep Limited Adr Borsa (IMMP) Ultime notizie
Immutep Limited (NASDAQ:IMMP) Shares Sold by Jane Street Group LLC - Defense World
Verition Fund Management LLC Has $57,000 Stock Position in Immutep Limited (NASDAQ:IMMP) - Defense World
Immutep Announces Initial Safety Data from First-in-Human Phase I Trial Evaluating IMP761 - The Manila Times
Immutep Announces Initial Safety Data from First-in-Human Phase I Trial Evaluating IMP761 - GlobeNewswire Inc.
Immutep shares new cancer study results - Investing.com
Immutep Quarterly Activities Report Q1 FY25 - GlobeNewswire
Immutep Announces First-in-Human Phase I Study of IMP761 Progresses to Dose Escalation Portion of Trial - The Manila Times
Immutep Limited ADR (IMMP) Stock: Navigating a Year of Stock Volatility - The InvestChronicle
Metric Deep Dive: Understanding Immutep Limited ADR (IMMP) Through its Ratios - The Dwinnex
Immutep reports positive results in cancer study - Investing.com
Dow Jumps Over 200 Points; NY Empire State Manufacturing Index Increases In September - Benzinga
Research Analysts Issue Forecasts for Immutep Limited’s FY2025 Earnings (NASDAQ:IMMP) - Defense World
Immutep Limited ADR (IMMP) Stock: Navigating a Year of Volatility - The InvestChronicle
Short Interest in Immutep Limited (NASDAQ:IMMP) Declines By 10.1% - Defense World
Immutep Announces First Participant Dosed in Phase I Study of IMP761, a First in Class Agonist LAG-3 Antibody - GlobeNewswire
Virtu Financial LLC Buys 32,864 Shares of Immutep Limited (NASDAQ:IMMP) - Defense World
Immutep reports steady progress in Q4 FY24 - Investing.com India
Immutep reports steady progress in Q4 FY24 By Investing.com - Investing.com Australia
Immutep Limited (NASDAQ:IMMP) Shares Acquired by BNP Paribas Financial Markets - Defense World
Immutep Announces Successful Meeting with FDA on Phase III Design in Non-Small Cell Lung Cancer - GlobeNewswire
Guess which ASX healthcare stock is surging on big FDA news - The Motley Fool
Why 29Metals, Immutep, Insignia, and Perenti shares are pushing higher today - The Motley Fool
FY2027 EPS Estimates for Immutep Limited (NASDAQ:IMMP) Cut by Capital One Financial - American Banking and Market News
Equities Analysts Set Expectations for Immutep Limited’s FY2029 Earnings (NASDAQ:IMMP) - American Banking and Market News
Immutep Limited (NASDAQ:IMMP) Short Interest Up 6.2% in June - American Banking and Market News
Immutep Receives Regulatory Clearance for Phase I Study of - GlobeNewswire
Baird cuts Immutep stock target on phase 2b trial results, retains Outperform - Investing.com
Stocks of the Hour: Adherium, Nanoveu, Nimy Resources - ShareCafe
Immutep appoints research institute to conduct first-in-human study of IMP761 - Biotech Dispatch
10 Best Australian Stocks To Buy - Yahoo Finance
Immutep LimitedADR (IMMP) Price Target Increased by 7.83% to 2.80 - MSN
Immutep Announces GMP Manufacturing Process Developed for - GlobeNewswire
Check Up: These 4 ASX healthcare stocks come with Strong Buy recommendations - Stockhead
The Daily Biotech Pulse: Moderna To Kickstart Phase 3 Study On July 27, Immutep Awarded Antibody Patent - Yahoo Finance
Immutep Ltd (IMMP) Stock Price, Trades & News - GuruFocus.com
Benzinga's Daily Biotech Pulse: Organovo Falls On Earnings; Celgene Gets New CFO - Yahoo Finance
Immutep Limited Adr Azioni (IMMP) Dati Finanziari
Non sono disponibili dati finanziari per Immutep Limited Adr (IMMP). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
0.65%
4.62%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):